Oleg Nodelman insider trades: Aktis Oncology (AKTS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Oleg reports to the SEC
and 1 more company
Open-market buys and sales
33 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | AKTS | ↑ Buy | 2,222,222 | $18.00 | $40.0M | See Note | Jan 12, 2026 (0d) |
| May 19, 2025 | ZYME | ↑ Buy | 55,421 | $11.47 | $636K | See Note | May 19, 2025 (0d) |
| Apr 17, 2025 | ZYME | ↑ Buy | 128,713 | $11.32 | $1.5M | See Note | Apr 18, 2025 (1d) |
| Apr 4, 2025 | ZYME | ↑ Buy | 317,208 | $11.42 | $3.6M | See Note | Apr 7, 2025 (3d) |
| Apr 2, 2025 | ZYME | ↑ Buy | 127,415 | $11.75 | $1.5M | See Note | Apr 2, 2025 (0d) |
| Mar 26, 2025 | ZYME | ↑ Buy | 97,349 | $12.61 | $1.2M | See Note | Mar 27, 2025 (1d) |
| Mar 24, 2025 | ZYME | ↑ Buy | 127,198 | $12.92 | $1.6M | See Note | Mar 24, 2025 (0d) |
| Mar 19, 2025 | ZYME | ↑ Buy | 228,463 | $12.55 | $2.9M | See Note | Mar 19, 2025 (0d) |
| Mar 13, 2025 | ZYME | ↑ Buy | 1,081,980 | $12.13 | $13.1M | See Note | Mar 13, 2025 (0d) |
| Jan 2, 2025 | ANAB | ↑ Buy | 85,098 | $12.92 | $1.1M | See Note | Jan 2, 2025 (0d) |
| Feb 21, 2023 | NUVB | ↑ Buy | 5,313,100 | $1.26 | $6.7M | See Notes | Sep 21, 2023 (212d) |
| May 5, 2022 | ANAB | ↓ Sell | 668,237 | $21.63 | $14.5M | See Note | May 9, 2022 (4d) |
| May 5, 2022 | ANAB | ↑ Buy | 668,237 | $21.63 | $14.5M | See Notes | May 9, 2022 (4d) |
| Nov 24, 2021 | NUVB | ↑ Buy | 371,410 | $8.96 | $3.3M | See Notes 2 and 3 | Nov 30, 2021 (6d) |
| Nov 24, 2021 | NUVB | ↑ Buy | 21,758 | $7.69 | $167K | See Notes 2 and 4 | Nov 30, 2021 (6d) |
| Jul 31, 2021 | NUVB | ↓ Sell | 208,142 | $9.96 | $2.1M | See Notes 2 and 4 | Nov 30, 2021 (122d) |
| May 4, 2021 | ANAB | ↑ Buy | 221,500 | $23.24 | $5.1M | See Note 1 | May 4, 2021 (0d) |
| Apr 27, 2021 | ANAB | ↑ Buy | 147,300 | $23.63 | $3.5M | See Note 1 | Apr 27, 2021 (0d) |
| Apr 13, 2021 | NUVB | ↑ Buy | 406,019 | $9.89 | $4.0M | See Notes 1 and 2 | Apr 13, 2021 (0d) |
| Apr 13, 2021 | NUVB | ↑ Buy | 58,481 | $9.89 | $578K | See Notes 1 and 3 | Apr 13, 2021 (0d) |
| Apr 9, 2021 | PANA | ↑ Buy | 545,000 | $10.00 | $5.5M | Direct | Apr 13, 2021 (4d) |
| Jul 6, 2020 | PANA | ↑ Buy | 390,000 | $10.00 | $3.9M | Direct | Jul 6, 2020 (0d) |
| Sep 29, 2014 | KIN | ↑ Buy | 55,590 | $9.56 | $531K | By EcoR1 Capital Fund Qualified, L.P. | Sep 30, 2014 (1d) |
| Sep 29, 2014 | KIN | ↑ Buy | 44,410 | $9.56 | $425K | By EcoR1 Capital Fund, L.P. | Sep 30, 2014 (1d) |
| Aug 28, 2014 | KIN | ↑ Buy | 25,793 | $10.85 | $280K | By EcoR1 Capital Fund Qualified, L.P. | Aug 29, 2014 (1d) |
| Aug 28, 2014 | KIN | ↑ Buy | 21,207 | $10.85 | $230K | By EcoR1 Capital Fund, L.P. | Aug 29, 2014 (1d) |
| Aug 26, 2014 | KIN | ↑ Buy | 46,780 | $10.50 | $491K | By EcoR1 Capital Fund Qualified, L.P. | Aug 27, 2014 (1d) |
| Aug 26, 2014 | KIN | ↑ Buy | 38,464 | $10.50 | $404K | By EcoR1 Capital Fund, L.P. | Aug 27, 2014 (1d) |
| May 27, 2014 | GNVC | ↑ Buy | 12,449 | $2.24 | $28K | By EcoR1 Capital Fund, L.P. | May 27, 2014 (0d) |
| May 27, 2014 | GNVC | ↑ Buy | 11,691 | $2.24 | $26K | By EcoR1 Capital Fund Qualified, L.P. | May 27, 2014 (0d) |
| Mar 28, 2014 | GNVC | ↑ Buy | 73,364 | $2.55 | $187K | By EcoR1 Capital Fund, L.P. | Mar 28, 2014 (0d) |
| Mar 28, 2014 | GNVC | ↑ Buy | 48,909 | $2.55 | $125K | By EcoR1 Capital Fund Qualified, L.P. | Mar 28, 2014 (0d) |
| Dec 12, 2013 | KIN | ↑ Buy | 400,000 | $7.00 | $2.8M | By EcoR1 Capital Fund, L.P. | Dec 13, 2013 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AKTS insiders
Open-market trades in the last 12 months
About Oleg Nodelman's insider trades
Oleg Nodelman is a director at Aktis Oncology (AKTS). Since Dec 12, 2013, Oleg has reported 31 open-market purchases worth $119.9M and 2 sales worth $16.5M on SEC Form 4. In the last 12 months: 1 buy ($40.0M).
Their filings also include grants and awards (4 filings), conversions (2 filings), option exercises (1 filing), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AKTS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.